| Literature DB >> 30111277 |
Gui-Ping Xu1, Wei-Xian Chen2, Wen-Yue Xie3, Li-Fang Wu4.
Abstract
BACKGROUND: The rs1520220 polymorphism in the insulin-like growth factor 1 (IGF1) gene has been reported to affect cancer susceptibly in several studies. However, the results of the relevant studies are inconsistent. We conduct a current meta-analysis to investigate the association between rs1520220 and cancer susceptibly.Entities:
Keywords: Cancer; IGF1; Meta-analysis; Polymorphism; rs1520220
Mesh:
Substances:
Year: 2018 PMID: 30111277 PMCID: PMC6094919 DOI: 10.1186/s12199-018-0727-y
Source DB: PubMed Journal: Environ Health Prev Med ISSN: 1342-078X Impact factor: 3.674
Fig. 1The flow diagram of included/excluded studies
Characteristics of the studies included in the meta-analysis
| First author | Year | Country/region | Ethnicity | Cancer type | Genotyping method | Control source |
|---|---|---|---|---|---|---|
| AI-Zahrani [ | 2006 | Europe | Caucasian | Breast cancer | TaqMan | PB |
| Chia [ | 2008 | USA | Mix | TGCT | TaqMan | PB |
| Patel [ | 2008 | USA or Europe | Mix | Breast cancer | TaqMan | PB |
| Ennishi [ | 2011 | Japan | Asian | Stomach cancer | TaqMan | HB |
| Nakao [ | 2011 | Japan | Asian | Pancreatic cancer | TaqMan | HB |
| Qian [ | 2011 | China | Asian | Breast cancer | TaqMan | HB |
| Simons [ | 2015 | Netherlands | Caucasian | Colorectal cancer | SEQUENOM® MassARRAY® | PB |
| Li [ | 2016 | China | Asian | Breast cancer | TaqMan | PB |
TGCT testicular germ cell tumors, PB population-based, HB hospital-based
IGF1 rs1520220 polymorphism genotype distribution and allele frequency in cases and controls
| Genotype ( | Allele frequency (N) | HWE | Score | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Control | Case | Control | |||||||||||
| Total | GG | GC | CC | Total | GG | GC | CC |
|
|
|
| |||
| AI-Zahrani [ | 2036 | 1388 | 569 | 79 | 2194 | 1525 | 617 | 52 | 3345 | 727 | 3667 | 721 | 0.261 | 15 |
| Chia [ | 568 | 378 | 169 | 21 | 698 | 452 | 209 | 37 | 925 | 211 | 1113 | 283 | 0.052 | 15 |
| Patel [ | 6584 | 329 | 2207 | 4048 | 8424 | 440 | 2707 | 5277 | 2865 | 10,303 | 3587 | 13,261 | < 0.001 | 12 |
| Ennishi [ | 703 | 148 | 357 | 198 | 1462 | 361 | 728 | 373 | 653 | 753 | 1450 | 1474 | 0.877 | 12 |
| Nakao [ | 176 | 33 | 97 | 46 | 1402 | 347 | 697 | 358 | 163 | 189 | 1391 | 1413 | 0.833 | 12 |
| Qian [ | 403 | 71 | 189 | 143 | 403 | 78 | 193 | 132 | 331 | 475 | 349 | 457 | 0.620 | 11 |
| Simons [ | 2274 | 85 | 691 | 1498 | 43,561 | 1384 | 12,689 | 29,488 | 861 | 3687 | 15,457 | 71,665 | 0.673 | 15 |
| Li [ | 140 | 38 | 58 | 44 | 160 | 36 | 69 | 55 | 134 | 146 | 141 | 179 | 0.113 | 12 |
HWE Hardy-Weinberg equilibrium
Meta-analysis of the association between IGF1 rs1520220 polymorphism and cancer susceptibility
| Subgroup | No. | C vs. G | CC vs. GG | GC vs. GG | CC + GC vs. GG | CC vs. GC + GG | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95%Cl) |
|
| OR (95%Cl) |
|
| OR (95%Cl) |
|
| OR (95%Cl) |
|
| OR (95%Cl) |
|
| ||
| Overall | 8 | 1.01 (0.95–1.08)* | 0.715 | 0.026 | 1.08 (0.90–1.30)* | 0.415 | 0.010 | 1.05 (0.97–1.13) | 0.268 | 0.374 | 1.05 (0.97–1.13) | 0.237 | 0.163 | 1.02 (0.91–1.13)* | 0.773 | 0.026 |
| Caucasian | 2 | 1.00 (0.84–1.20)* | 0.953 | 0.010 | 1.16 (0.58–2.31)* | 0.675 | 0.001 | 0.98 (0.87–1.10) | 0.743 | 0.330 | 0.97 (0.77–1.21)* | 0.762 | 0.08 | 1.21 (0.68–2.15)* | 0.524 | 0.002 |
| Asian | 4 |
|
| 0.455 |
|
| 0.426 | 1.17 (0.99–1.39) | 0.066 | 0.382 |
|
| 0.324 | 1.10 (0.95–1.26) | 0.215 | 0.762 |
| Breast cancer | 4 | 1.00 (0.95–1.05) | 0.978 | 0.130 | 1.15 (0.87–1.51)* | 0.320 | 0.053 | 1.04 (0.94–1.15) | 0.425 | 0.713 | 1.05 (0.96–1.15) | 0.289 | 0.703 | 1.11 (0.86–1.42)* | 0.428 | 0.016 |
| Quality score ≥ 12 | 7 | 1.01 (0.94–1.08)* | 0.875 | 0.021 | 1.07 (0.87–1.31)* | 0.542 | 0.006 | 1.04 (0.96–1.13) | 0.292 | 0.275 | 1.04 (0.97–1.12) | 0.283 | 0.112 | 1.01 (0.90–1.13)* | 0.922 | 0.023 |
OR odds ratio, 95% CI 95% confidence interval, POR, pool p value; P, p value of heterogeneity test
*Indicates that the OR, 95% Cl, and corresponding POR were calculated based on the random-effects model; otherwise, the fixed-effects model was used. Italic values are statistically significant (P < 0.05)
Fig. 2Stratification analyses by ethnicity between IGF1 rs1520220 polymorphism and cancer susceptibility. a Allele model. b Homozygous model, c Heterozygous model. d Dominant model. e Recessive model. The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight. The diamond represents the summary OR and 95% CI. The fixed-effects model was used
Fig. 3Sensitivity analyses between IGF1 rs1520220 polymorphism and cancer susceptibility. a Allele model. b Homozygous model. c Heterozygous model. d Dominant model. e Recessive model. a, b, and e, the random-effects model was used. For c and d, the fixed-effects model was used
Fig. 4Funnel plot for publication bias test. a Allele model. b Homozygous model. c Heterozygous model. d Dominant model. e Recessive model
Publication bias analysis
| Genetic model | Egger’s test | Begg’s test | ||
|---|---|---|---|---|
|
| 95%Cl |
|
| |
| C vs. G | 0.85 | − 1.731~3.568 | 0.429 | 0.902 |
| CC vs. GG | 0.23 | − 3.080~3.724 | 0.824 | 0.902 |
| GC vs. GG | 0.14 | − 2.255~2.537 | 0.890 | 1.000 |
| CC + GC vs. GG | − 0.09 | − 2.981–2.760 | 0.928 | 0.902 |
| CC vs. GC + GG | 1.11 | − 1.099–2.912 | 0.311 | 0.902 |